Core Viewpoint - *ST Suwu has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), indicating that the company may face major illegal delisting due to inflated revenue, costs, and profits in its annual reports from 2020 to 2023 [2][5][7]. Summary by Relevant Sections Administrative Penalty Notice - The notice states that *ST Suwu's subsidiaries engaged in non-commercial trade activities with related companies, leading to inflated financial figures [5][7]. - The company is at risk of being delisted under the Shanghai Stock Exchange's rules due to these violations [2][10]. Financial Impact - The inflated revenue figures from 2020 to 2023 were reported as follows: - 2020: 495 million yuan (26.46%) - 2021: 469 million yuan (26.39%) - 2022: 431 million yuan (21.26%) - 2023: 377 million yuan (16.82%) [7]. - The inflated costs were: - 2020: 481 million yuan (37.08%) - 2021: 448 million yuan (35.47%) - 2022: 411 million yuan (28.40%) - 2023: 355 million yuan (20.95%) [7]. - The inflated profit figures were: - 2020: 14.58 million yuan (2.89%) - 2021: 20.27 million yuan (51.65%) - 2022: 19.92 million yuan (26.42%) - 2023: 21.22 million yuan (29.81%) [7]. Company Response and Future Actions - *ST Suwu has issued its first risk warning regarding the potential for major illegal delisting [8]. - If the company receives a formal penalty decision confirming the violations, it will apply for a trading suspension and disclose relevant information [10]. - The Shanghai Stock Exchange will issue a notice regarding the potential termination of *ST Suwu's stock listing within five trading days of the suspension [10]. Recent Financial Performance - For the year 2024, *ST Suwu reported: - Revenue of 1.599 billion yuan, a decrease of 28.64% year-on-year - Net profit attributable to shareholders of 70.48 million yuan, compared to a loss of 71.95 million yuan in 2023 [10][11].

【 导读 】*ST苏吴收到《行政处罚事先告知书》， 或 被实施重大违法强制退市 中国基金报记者 闻言 7月13日晚间， *ST苏吴 发布 公告称，公司收到中国证监会下发的《行政处罚事先告知书》，认定公司虚增营业收入、营业成本和利润， 2020年至2023年年报存在虚假记载。 《行政处罚事先告知书》显示，*ST苏吴的上述事项将触及《上海证券交易所股票上市规则》第9.5.2条第一款第（六）项规定的重大违法 强制退市情形， 可能被实施重大违法强制退市。 自7月14日起，*ST苏吴将被叠加实施退市风险警示。截至7月11日收盘，*ST苏吴股价报2.42元/股，总市值为17.23亿元。 2020年至2023年年报存在多项虚假记载 公告显示，7月13日，*ST苏吴收到《行政处罚事先告知书》，监管认定*ST苏吴的子公司江苏吴中进出口有限公司、中吴贸易发展（杭 州）有限公司、江苏吴中海利国际贸易有限公司通过与浙江优诺德贸易有限公司等多家关联公司开展无商业实质的贸易业务，虚增营业收 入、营业成本和利润。 此外，《行政处罚事先告知书》显示，*ST苏吴未如实披露实际控制人，2018年至2023年年报存在虚假记载；未按规定披露关联方非 ...

为香港股市"打广告"，吸引更多内地企业赴港上市及借道香港"出海"，算是李家超邀请"二小龙"的"附带收获" 上周，香港特区行政长官李家超一连三天（7月9日至11日）与特首顾问团举行午餐会，听取顾问团成员就今年《施政报告》和香港整体发展的意见。 第一财经记者注意到，这是新一届（第二届）特首顾问团成员的首次会议。顾问团出现三位新成员，分别为著名经济学家朱民、浙江强脑科技有限公司创始 人韩璧丞及杭州宇树科技有限公司创始人王兴兴——强脑科技和宇树科技都是"杭州六小龙"企业。 相应地，首届特首顾问团成员中的三人不再出现，分别是李嘉诚长子、长和集团主席李泽钜，华润集团前董事长傅育宁，以及已经去世的商汤科技创始人汤 晓鸥。顾问团继续保持34人阵容不变。 特首顾问团是李家超于2023年主导成立的高层次咨询组织，分为经济高质量与持续发展，创新与创业，以及区域与环球协作三个小组。成员均为来自政、 商、学、律界的翘楚，像香港特区前财政司司长唐英年、太古集团主席白德利、阿里巴巴创始人之一蔡崇信、诺贝尔经济学奖得主迈克尔·斯彭斯等。公开 信息显示，首届顾问团至少与李家超举行了三次正式会议。 李家超主持特首顾问团午餐会议，图为其中一场会议 ...

证券代码：605016 证券简称：百龙创园 公告编号：2025-033 山东百龙创园生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | | 项 | 目 | 本报告期 | 上年同期 | | 增减变动幅度（％） | | 营业总收入 | | 64,976.12 | 53,134.84 | | 22.29 | | 营业利润 | | 20,132.02 | 13,638.84 | | 47.61 | | 利润总额 | | 20,089.00 | 13,640.60 | | 47.27 | | 归属于上市公司股东的净利润 | | | 17,058.97 | 11,956.23 | 42.68 | | 归属于上市公司股东的扣除非 | | | | | | | 经常性损益的净利润 | | | | | | | 基本每股收益（元） | | | 0.41 | 0.37 | 10.81 | | 加权平均净资产收益率 ...

潮水般的商机正涌向中国制造，中东成为"破局"新大陆。 当东南亚市场增长渐缓，欧美传统市场贸易壁垒高筑，全球企业的目光正被一片曾经被低估的区域所吸引——历经 深刻经济转型的中东地区，以令人瞩目的速度，崛起为中国制造出海版图上最具潜力的"新蓝海"。 2025年广交会的数据清晰映射了这一巨变：中东采购商比例创纪录地达到14.3%，首次超越欧美客商，登顶"最积极 下订单"区域。同时，常年占据电商健康榜榜首的老龄养护科技品"青益莱PAIOTIDE"，同样吸引了中东高端消费群体 的青睐。 这种转变在产业层面同样显著。一位来自上海的自动化设备制造商直言："客户重心已明确转向印度、中东、非洲、 土耳其等新兴市场，欧美不再是我们的'默认主场'。" 目前，在国内京东等线上平台，包括"青益莱"在内的国产口服科技品，出货、成交等均力压洋牌，好评率达99%。而 在国际市场，浦东海关机场数据曾统计，赴美包裹占比在一半以上。 多家国内厂商证实，来自中东地区的客户咨询邮件激增，相关出口商更透露，该区域订单量呈现爆发式增长，生产 线正开足马力、通宵达工以满足交付需求。 这些中东买家提出的要求高度一致且明确：从设计研发、原材料采购、零部件制造到 ...

Core Viewpoint - Anxuyuan has received feedback from the China Securities Regulatory Commission regarding its application for a Hong Kong IPO, highlighting compliance and operational concerns, as well as its financial performance over the past two years [1][2]. Group 1: Regulatory Feedback - The company is required to clarify the establishment, type, operation, and beneficiary arrangements of the Axbio Talent Limited trust [1]. - Compliance issues regarding the offshore structure and reverse mergers need to be addressed, including foreign exchange management, tax compliance, and the fairness of acquisition pricing for its subsidiaries [1]. - The company must provide details on external consultants involved in incentive arrangements, including contract specifics and responsibilities [1]. Group 2: Business Operations - Anxuyuan is involved in developing and operating various digital platforms and must disclose user data collection practices and security measures [2]. - The company has submitted its listing application to the Hong Kong Stock Exchange, with CICC and浦银国际 as joint sponsors, despite reporting continuous losses over the past two years [2]. - Founded in 2016, Anxuyuan specializes in integrated circuit biotechnology, with its core product being the AxiLona EL-100, a molecular diagnostic tool [2]. Group 3: Financial Performance - The company reported no revenue in 2023 and projected revenue of $479,000 in 2024, with losses of $22.856 million and $23.466 million for the respective years [2]. - Adjusted net losses were $19.68 million in 2023 and $14.66 million in 2024 [2]. - As of December 31, 2024, the company had a net debt of $58.27 million and cash and cash equivalents of $36.91 million [2].

中新网海口7月12日电 (记者 张茜翼)鱼鳞、鱼皮、鱼内脏，能做什么？在海南，一家企业将这些鱼类副 产物资源充分利用，加工成高附加值的营养保健品，产品远销50多个国家和地区。 7月11日，参加2025海外华裔大学生海南研习活动的15名海外华裔大学生走进海口国家高新区，见证海 南自贸港建设下的产业升级与技术创新。 7月11日，参加2025海外华裔大学生海南研习活动的华裔学子走进海口国家高新技术产业开发区，参访 海南华研胶原科技股份有限公司。 中新网记者 骆云飞 摄 在海南华研胶原科技股份有限公司(下称"海南华研")的生物多肽透明车间内，自动化设备高效运转，鱼 胶原蛋白肽的提取、打包一气呵成。原料经过定向酶切、过滤、浓缩等密闭工序后，最终成为干燥的粉 状肽。 本，零关税政策则减少了设备采购费用。"封关后，贸易成本进一步降低，企业能更灵活地拓展全球市 场。" 参加2025海外华裔大学生海南研习活动的华裔学子参访海南维力医疗科技开发有限公司。 中新网记者 骆云飞 摄 在海南维力医疗科技开发有限公司，华裔大学生们参观了自动化的乳胶导尿管生产车间。据该公司总经 理助理杨瑞锦介绍，企业自主研发出自动化生产线，日均产量约30 ...

Group 1: Market Performance - Energy sector ETF increased by 0.45%, closing at 89.13 with a volume of 15.08 million shares and a market cap of $22.32 billion, reflecting a 5.72% increase [1][2] - Consumer discretionary ETF rose by 0.03%, closing at 221.43 with a volume of 3.35 million shares and a market cap of $27.81 billion, showing a slight decline of 0.82% [1][2] - Global airline ETF decreased by 2.26%, closing at 25.03 with a volume of 3.13 million shares and a market cap of $78.84 million, indicating a 1.26% decline [1][2] Group 2: Sector Specifics - Biotechnology index ETF fell by 1.54%, closing at 131.59 with a volume of 1.65 million shares and a market cap of $10.45 billion, down by 0.38% [1][2] - Regional bank ETF declined by 1.07%, closing at 62.89 with a volume of 1.40 million shares and a market cap of $5.25 billion, reflecting a 5.63% increase [1][2] - Financial sector ETF dropped by 1.04%, closing at 52.16 with a volume of 30.29 million shares and a market cap of $58.06 billion, showing an 8.69% increase [1][2]

Core Viewpoint - The company announced a cash dividend distribution of 0.8 yuan per share for the fiscal year 2024, totaling approximately 101.67 million yuan for all shareholders [2][4]. Summary by Relevant Sections Dividend Distribution Plan - The profit distribution plan was approved at the annual shareholders' meeting held on May 22, 2025 [2]. - The total share capital before the distribution is 127,082,805 shares, with a total cash dividend of 101,666,244 yuan [4]. Distribution Objects - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the dividend record date [3]. Implementation Method - The dividends for unrestricted circulating shares will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [4]. - Shareholders who have completed designated trading can receive their cash dividends on the distribution date at their designated securities business department [4]. Taxation on Dividends - For individual shareholders holding unrestricted circulating shares for over one year, the cash dividend of 0.8 yuan per share is exempt from personal income tax [8]. - For shares held for one year or less, the tax will be calculated upon the transfer of shares, with a maximum effective tax rate of 20% for shares held for one month or less [8]. - For limited circulating shares, the tax treatment varies, with a post-tax dividend of 0.72 yuan per share for certain categories of shareholders [9][10]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's securities department at 0571-85391552 [10].

今天大盘低开高走，到收盘涨幅回落。 大盘整体上涨，还在4.8星。 大中小盘股都上涨，小盘股上涨多一些。 价值风格下跌。 文 | 银行螺丝钉 （转载请注明出处） 银行指数盘中一度上涨，触及高估，不过随后银行指数大幅下跌。 拖累价值风格整体低迷。 银行指数下跌后，也暂时不太便宜。 成长风格高比较强势，医药医疗、生物科技上涨较多。 港股也整体上涨，港股科技领涨。 现在越来越有进入右侧的迹象了。 今年大盘、中小盘、价值、成长，都有表现的阶段。 不过随着上涨，像去年5点几星，低估品种一抓一大把的情况，现在也逐渐减少了。 机会是跌出来的，风险是涨出来的。 1. 有朋友问最近港股科技品种相对低迷，还会有发力的阶段么？ 港股科技股最近一年多的涨跌，其实比较有特点。 这里以港股科技指数为例。 港股科技相关的指数也比较多。 其中中证指数公司编制的是港股科技指数，成分股数量多一些（50只）。 恒生指数公司编制的是恒生科技指数，成分股数量少一些（30只上下）。 两个指数比较重合，估值位置也相似，区别在于港股科技股票更多，也增加了一些医药生物科技方面的股票。类似恒生科技+恒生医疗的效果。 像最近的美团阿里京东"外卖大战"，其实在港股科 ...